In Brief: Hexagen
Executive Summary
Hexagen: First round funding raises $6.2 mil. for the Cambridge, England-based functional genomics company. Abingworth Management, New Enterprise Associates and Schroder Ventures participate. Hexagen will use proceeds to establish operations. Hexagen's proprietary technology enables the company "to quickly produce variants in any gene for which the DNA sequence is known, enabling the function of that gene to be studied." Hexagen is led by CEO Mark Bodmer, PhD, formerly Celltech director of biology, and President Andrew Sandham, previously Roche U.K. business development director and Cantab chief operating officer...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth